News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in MedicineShorts
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Emerging Pharma Leaders Awards|
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
News|Slideshows|June 30, 2025

June Pharmaceutical Industry Movers & Shakers

Author(s)Don Tracy, Associate Editor

A monthly roundup of business and people news in the pharmaceutical industry.

Advertisement

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement
Pharmaceutical Executive daily

Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer

ByNicholas Jacobus
April 10th 2026

Why Branding is Pharma’s Most Undervalued Asset

ByMichael Christel,Ken Banta,Andy Milligan
April 10th 2026
Stock.adobe.com glp-1

New Study Reveals Genetic Predictors for GLP-1 Weight Loss and Side Effects

ByNicholas Jacobus
April 10th 2026
Stock.adobe.com small cell lung cancer

Amgen’s Tarlatamab Approved in China

ByNicholas Jacobus
April 10th 2026

The Complex Usage and Impact of GLP-1 Usage: Q&A with Mark Bagnall

ByMike Hollan,Mark Bagnall
April 10th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Shionogi Inc. Awarded $482 Million Contract with U.S. Government to Enhance National Preparedness for Drug-Resistant Bacterial Threats

2

Pharmaceutical Executive Daily: China Approves Amgen's Tarlatamab for Previously Treated Extensive-Stage Small Cell Lung Cancer

3

Amgen’s Tarlatamab Approved in China

4

Q&A: Supply Chain Fallout From Iran War, Tariff Uncertainty

5

New Study Reveals Genetic Predictors for GLP-1 Weight Loss and Side Effects

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us